Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Gifu 501-1196, Japan.
Education Center of Green Pharmaceutical Sciences, Gifu Pharmaceutical University, Gifu 502-8585, Japan.
Cells. 2021 May 12;10(5):1179. doi: 10.3390/cells10051179.
Several anticancer drugs including cisplatin (CDDP) induce hypomagnesemia. However, it remains fully uncertain whether Mg deficiency affects chemosensitivity of cancer cells. Here, we investigated the effect of low Mg concentration (LM) on proliferation and chemosensitivity using human lung adenocarcinoma A549 cells. Cell proliferation was reduced by continuous culture with LM accompanied with the elevation of G1 phase proportion. The amounts of reactive oxygen species (ROS) and stress makers such as phosphorylated-ataxia telangiectasia mutated and phosphorylated-p53 were increased by LM. Cell injury was dose-dependently increased by anticancer drugs such as CDDP and doxorubicin (DXR), which were suppressed by LM. Similar results were obtained by roscovitine, a cell cycle inhibitor. These results suggest that LM induces chemoresistance mediated by ROS production and G1 arrest. The mRNA and protein levels of ATP binding cassette subfamily B member 1 (ABCB1) were increased by LM and roscovitine. The LM-induced elevation of ABCB1 and nuclear p38 expression was suppressed by SB203580, a p38 MAPK inhibitor. PSC833, an ABCB1 inhibitor, and SB203580 rescued the sensitivity to anticancer drugs. In addition, cancer stemness properties were suppressed by SB203580. We suggest that Mg deficiency reduces the chemotherapy sensitivity of A549 cells, although it suppresses cell proliferation.
几种抗癌药物包括顺铂(CDDP)可诱导低镁血症。然而,镁缺乏是否会影响癌细胞的化疗敏感性仍完全不确定。在这里,我们使用人肺腺癌细胞 A549 研究了低镁浓度(LM)对增殖和化疗敏感性的影响。连续培养在 LM 中伴随着 G1 期比例的升高,细胞增殖减少。活性氧(ROS)和应激标志物如磷酸化共济失调毛细血管扩张突变和磷酸化-p53 的数量增加。ROS 生成和 G1 期阻滞介导的抗癌药物如 CDDP 和多柔比星(DXR)引起的细胞损伤呈剂量依赖性增加,而 LM 可抑制这种损伤。细胞周期抑制剂罗司维亭也得到了类似的结果。这些结果表明,LM 诱导由 ROS 产生和 G1 期阻滞介导的化疗耐药性。ABCB1 基因和蛋白水平在 LM 和罗司维亭作用下增加。LM 诱导的 ABCB1 和核 p38 表达升高被 p38 MAPK 抑制剂 SB203580 抑制。ABCB1 抑制剂 PSC833 和 SB203580 恢复了对抗癌药物的敏感性。此外,SB203580 抑制了癌症干细胞特性。我们认为,尽管镁缺乏抑制细胞增殖,但会降低 A549 细胞的化疗敏感性。